Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma

Lilian Schwarz, Matthew Harold G. Katz

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

Borderline resectable pancreatic cancer represents a subcategory of advanced cancer that is typically defined by limited involvement of the major mesenteric vasculature. Such involvement is associated with a high likelihood of microscopically incomplete resection if surgery is used as the primary therapeutic modality. Increasing data support the role of neoadjuvant therapy as part of multimodality management but there is no uniformly accepted standard of care. This review discusses, based on recent literature and the experience of the Pancreatic Tumor Study Group at The University of Texas MD Anderson Cancer Center, the classification, definition, diagnosis, and management of borderline resectable pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)727-740
Number of pages14
JournalHematology/Oncology Clinics of North America
Volume29
Issue number4
DOIs
StatePublished - Aug 1 2015

Keywords

  • Borderline resectable
  • Chemoradiation
  • Chemotherapy
  • Neoadjuvant therapy
  • Pancreatic cancer
  • Pancreatoduodenectomy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma'. Together they form a unique fingerprint.

Cite this